去泛素化酶OTUB2与肿瘤发生发展关系的研究进展

doi:10.13481/j.1671-587X.20250634

Abstract

Abstract:

Deubiquitinating enzymes are important hydrolases in the protein ubiquitin system， which regulate the dynamic balance of protein ubiquitination and deubiquitination by reversing ubiquitination， and play important roles in biological processes such as regulating protein stability， cell signal transduction， and cell apoptosis. As a member of the deubiquitinating enzyme family， ovarian tumor domain-containing protease （OTU） domain ubiquitin aldehyde binding 2 （OTUB2） can play a key role in DNA damage， signal transduction， cell metabolism， and tumorigenesis by regulating the ubiquitination levels of various substrates. OTUB2 can be abnormally expressed in various cancers， and as a regulatory factor， it significantly affects the growth， development， proliferation， migration， and invasion of cancer cells， and is closely related to the prognosis of the patients， potentially becoming a novel cancer therapeutic target and prognostic biomarker. Currently， there are many studies on the molecular mechanisms of OTUB2， but there are few review reports focusing on its role in cancer. Based on the research results about OTUB2 at home and abroad， this article reviewed the biological function of OTUB2， related signaling pathways， and its latest progress in cancer research， analyzed the application of OTUB2 in cancer treatment and prognosis evaluation， and provided new ideas for future research on OTUB2.

Key words: Deubiquitinating enzyme, OTUB2, Signal transduction, Tumor, Signal pathway

CLC Number:

R262

Hongfei WANG,Guangquan LI. Research progress in relationship between deubiquitinase OTUB2 and occurrence and development of tumor[J].Journal of Jilin University(Medicine Edition), 2025, 51(6): 1763-1770.

References 42

[1]	DEWSON G， EICHHORN P J A， KOMANDER D. Deubiquitinases in cancer［J］. Nat Rev Cancer， 2023， 23（12）： 842-862.
[2]	BALAKIREV M Y， TCHERNIUK S O， JAQUINOD M， et al. Otubains： a new family of cysteine proteases in the ubiquitin pathway［J］. EMBO Rep， 2003， 4（5）： 517-522.
[3]	DU J S， FU L， SUI Y L， et al. The function and regulation of OTU deubiquitinases［J］. Front Med， 2020， 14（5）： 542-563.
[4]	NANAO M H， TCHERNIUK S O， CHROBOCZEK J， et al. Crystal structure of human otubain 2［J］. EMBO Rep， 2004， 5（8）： 783-788.
[5]	MEVISSEN T E， HOSPENTHAL M K， GEURINK P P， et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis［J］. Cell， 2013， 154（1）： 169-184.
[6]	XUE C Y， GREENE E C. DNA repair pathway choices in CRISPR-Cas9-mediated genome editing［J］. Trends Genet， 2021， 37（7）： 639-656.
[7]	WAN Q Y， CHEN Q， CAI D G， et al. OTUB2 promotes homologous recombination repair through stimulating Rad51 expression in endometrial cancer［J］. Cell Transplant， 2020， 29： 963689720931433.
[8]	DEMEYER A， BENHELLI-MOKRANI H， CHÉNAIS B， et al. Inhibiting homologous recombination by targeting RAD51 protein［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（2）： 188597.
[9]	NAKADA S. Opposing roles of RNF8/RNF168 and deubiquitinating enzymes in ubiquitination-dependent DNA double-strand break response signaling and DNA-repair pathway choice［J］. J Radiat Res， 2016， 57 （）： i33-i40.
[10]	KATO K， NAKAJIMA K， UI A， et al. Fine-tuning of DNA damage-dependent ubiquitination by OTUB2 supports the DNA repair pathway choice［J］. Mol Cell， 2014， 53（4）： 617-630.
[11]	MENG Z P， MOROISHI T， GUAN K L. Mechanisms of Hippo pathway regulation［J］. Genes Dev， 2016， 30（1）： 1-17.
[12]	ZHANG Z K， DU J J， WANG S， et al. OTUB2 promotes cancer metastasis via hippo-independent activation of YAP and TAZ［J］. Mol Cell， 2019， 73（1）： 7-21.
[13]	LIU L， CHENG H， JI M， et al. OTUB2 regulates YAP1/TAZ to promotes the progression of esophageal squamous cell carcinoma［J］. Biol Proced Online， 2022， 24（1）： 10.
[14]	PIKARSKY E， PORAT R M， STEIN I， et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer［J］. Nature， 2004， 431（7007）： 461-466.
[15]	BAUD V， KARIN M. Is NF-kappaB a good target for cancer therapy？ Hopes and pitfalls［J］. Nat Rev Drug Discov， 2009， 8（1）： 33-40.
[16]	LIU F， XIA Y， PARKER A S， et al. IKK biology［J］. Immunol Rev， 2012， 246（1）： 239-253.
[17]	CHEN Z J. Ubiquitination in signaling to and activation of IKK［J］. Immunol Rev， 2012， 246（1）： 95-106.
[18]	LI S， ZHENG H， MAO A P， et al. Regulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6［J］. J Biol Chem， 2010， 285（7）： 4291-4297.
[19]	MA Y F， SUN Y. MiR-29a-3p inhibits growth， proliferation， and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2［J］. Cancer Manag Res， 2019， 11： 13-23.
[20]	GU Z L， HUANG J， ZHEN L L. Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-κB signaling［J］. Kaohsiung J Med Sci， 2020， 36（6）： 399-404.
[21]	REVATHIDEVI S， MUNIRAJAN A K. Akt in cancer： mediator and more［J］. Semin Cancer Biol， 2019， 59： 80-91.
[22]	LIU G Y， SABATINI D M. mTOR at the nexus of nutrition， growth， ageing and disease［J］. Nat Rev Mol Cell Biol， 2020， 21（4）： 183-203.
[23]	LI J， CHENG D D， ZHU M X， et al. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer［J］. Theranostics， 2019， 9（1）： 179-195.
[24]	LU J R， TAN M， CAI Q S. The Warburg effect in tumor progression： mitochondrial oxidative metabolism as an anti-metastasis mechanism［J］. Cancer Lett， 2015， 356（2 Pt A）： 156-164.
[25]	SONG Y， WU Q W. RBM15 m⁶A modification-mediated OTUB2 upregulation promotes cervical cancer progression via the AKT/mTOR signaling［J］. Environ Toxicol， 2023， 38（9）： 2155-2164.
[26]	YU S Y， ZANG W C， QIU Y C， et al. Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis［J］. Oncogene， 2022， 41（1）： 46-56.
[27]	ZHANG Q， ZHANG J， YAO A M， et al. OTUB2 promotes the progression of endometrial cancer by regulating the PKM2-mediated PI3K/AKT signaling pathway［J］. Cell Biol Int， 2023， 47（2）： 428-438.
[28]	HU G， YANG J W， ZHANG H W， et al. OTUB2 promotes proliferation and migration of hepatocellular carcinoma cells by PJA1 deubiquitylation［J］. Cell Mol Bioeng， 2022， 15（3）： 281-92.
[29]	XU X， WU G T， HAN K K， et al. Inhibition of OTUB2 suppresses colorectal cancer cell growth by regulating β-Catenin signaling［J］. Am J Cancer Res， 2023， 13（11）： 5382-5393.
[30]	DOUMPAS N， LAMPART F， ROBINSON M D， et al. TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes［J］. EMBO J， 2019， 38（2）：e98873.
[31]	LIU K C， ZHAO T T， WANG J K， et al. Etiology， cancer stem cells and potential diagnostic biomarkers for esophageal cancer［J］. Cancer Lett， 2019， 458： 21-28.
[32]	ZHANG Y W， ZHANG H M， WANG C Y， et al. circRNA6448-14/miR-455-3p/OTUB2 axis stimulates glycolysis and stemness of esophageal squamous cell carcinoma［J］. Aging， 2024， 16（11）： 9485-9497.
[33]	CHANG W， LUO Q Y， WU X W， et al. OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis［J］. Cell Rep， 2022， 41（4）： 111561.
[34]	REN W F， XU Z L， CHANG Y T， et al. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1［J］. Nat Commun， 2024， 15（1）： 9.
[35]	YI M， ZHENG X L， NIU M K， et al. Combination strategies with PD-1/PD-L1 blockade： current advances and future directions［J］. Mol Cancer， 2022， 21（1）： 28.
[36]	HU X L， WANG J， CHU M， et al. Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy［J］. Mol Ther， 2021， 29（3）： 908-919.
[37]	NAN Y B， WU X W， LUO Q Y， et al. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition［J］. Proc Natl Acad Sci U S A， 2024， 121（19）： e2315348121.
[38]	NANDI D， CHEEMA P S， JAISWAL N， et al. FoxM1： Repurposing an oncogene as a biomarker［J］. Semin Cancer Biol， 2018， 52（Pt 1）： 74-84.
[39]	XIAO J， WANG L Q， ZHUANG Y， et al. The deubiquitinase OTUB2 promotes cervical cancer growth through stabilizing FOXM1［J］. Am J Transl Res， 2024， 16（1）： 75-84.
[40]	PERONE Y， FARRUGIA A J， RODRÍGUEZ-MEIRA A， et al. SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer［J］. Nat Commun， 2019， 10（1）： 2115.
[41]	OUYANG S W， ZENG Z Y， LIU Z， et al. OTUB2 regulates KRT80 stability via deubiquitination and promotes tumour proliferation in gastric cancer［J］. Cell Death Discov， 2022， 8（1）： 45.
[42]	SONG H， XU Y X， XU T， et al. CircPIP5K1A activates KRT80 and PI3K/AKT pathway to promote gastric cancer development through sponging miR-671-5p［J］. Biomedecine Pharmacother， 2020， 126： 109941.

Research progress in relationship between deubiquitinase OTUB2 and occurrence and development of tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[2]	Changfeng LIU,Guangjun JIN,Yonggang WANG. Primary renal angiosarcoma with multiple abdominal haemorrhages： A case repert and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 821-827.
[3]	Qiuping SU,Lei XING,Wei ZHANG,Shan JIANG,Yangyang ZHAO,Fangfang CHEN. Research progress in anti-tumor mechanism of berberine and application of its novel nano-delivery system in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 863-871.
[4]	Yang YU,Sheyu YE,Kexin WEI,Zhicheng WANG. Research progress in formation mechanism of tumor radioresistance and inhibitory effect of low-dose radiotherapy combination with novel sensitization strategies on tumor radioresistance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 872-880.
[5]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[6]	Yu ZHAO,Xiaoshuang HE,Xiaoyin DONG,Fengyi GAO,Jiageng HE. Regulatory effect of lncRNA urothelial carcinoembryonic antigen 1 on anoikis in human gastrointestinal stromal tumor cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 429-439.
[7]	Shuangji LI,He SHI,Yiwen QIN,Xiang LI,Yuyang LI,Weiwei LIU,Jia LI. Desmoplastic fibroma of mandible: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 246-251.
[8]	Luyao WANG,Chenxi ZHAO,Jincheng DU,Linlin LIU. Research progress in effect of Toll-like receptor 7/8 on occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 264-271.
[9]	Rongmian YAN,Xinting SUN,Xin GUAN,Yu CHENG,Liying HAN. Effects of KLK5 overexpression on growth of subcutaneous xenograft tumor and cisplatin sensitivity in nude mice [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1194-1203.
[10]	Yingran YANG,Jing WANG,Youzheng QIU,Shanshan ZHANG,Na LI,Wei SHEN,Ying CHEN,Ning WANG. Inhibitory effect of IFN-γ on proliferation of neuroblastoma cells and clinical significance of SULT2B1 protein expression in neuroblastoma tissue [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1267-1273.
[11]	Di QIN,Lihong HUAGN,Qingshuang ZHENG,Jingjing SUN,Weimin XU. Analysis on correlation between serum pro-inflammatory cytokines and muscle mass in elderly patients with sarcopenic obesity and diabetes [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1293-1302.
[12]	Ming CHEN,Qinghua LUO,Hongguang JIN,Liang HAN. Atypical lipomatous tumor of left lower limb: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1384-1389.
[13]	Jia YANG,Lingling TONG,Jinshu MA,Huafeng GENG. Misdiagnosis of ovarian sclerosing stromal tumor as malignant tumor: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1115-1120.
[14]	Hongjie LI,Maozhuo LAN,Xiao WANG,Ranran FENG,Yanyan TAO,Jiaqing LIU,Haibai SUN. Effect of BTK inhibitor BGB-3111 combined with bortezomib on apoptosis of human multiple myeloma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 599-609.
[15]	Xinyi YU,Zhifang JIA,Yuzheng ZHANG,Yuchen PAN,Yangyu ZHANG,Yanhua WU,Donghui CAO,Jing JIANG. Analysis on distribution and trend of malignant tumor incidence and mortality in Dehui City and Yanji City in Jilin Province from 2009 to 2016 [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 797-806.